Ensysce Biosciences, Inc. (ENSC) stock
ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.37−0.01 (-3.62%)
Close on Nov 18, 2026Market cap $7.20MP/E –Yield –
Ensysce Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Ensysce Biosciences's revenue for the twelve months ending Jun 30, 2026 was $4.50M, down 39.3% year over year. For fiscal 2025 it was $5.07M, down 2.8% from the year before. The highest annual figure on record is $5.21M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.07M | -2.8% |
| FY2024 | Dec 31, 2024 | $5.21M | +133.6% |
| FY2023 | Dec 31, 2023 | $2.23M | -11.6% |
| FY2022 | Dec 31, 2022 | $2.52M | -28.5% |
| FY2021 | Dec 31, 2021 | $3.53M | -10.2% |
| FY2020 | Dec 31, 2020 | $3.93M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.16M | -15.1% |
| Q1 FY2026 | Mar 31, 2026 | $961.00K | -27.2% |
| Q4 FY2025 | Dec 31, 2025 | $1.88M | +44.4% |
| Q3 FY2025 | Sep 30, 2025 | $493.10K | -85.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.37M | +654.4% |
| Q1 FY2025 | Mar 31, 2025 | $1.32M | +331.7% |
| Q4 FY2024 | Dec 31, 2024 | $1.30M | +153.1% |
| Q3 FY2024 | Sep 30, 2024 | $3.42M | +685.3% |
| Q2 FY2024 | Jun 30, 2024 | $181.80K | -62.9% |
| Q1 FY2024 | Mar 31, 2024 | $305.72K | -61.3% |
| Q4 FY2023 | Dec 31, 2023 | $515.03K | -64.1% |
| Q3 FY2023 | Sep 30, 2023 | $435.38K | +55.9% |
| Q2 FY2023 | Jun 30, 2023 | $490.47K | +136.4% |
| Q1 FY2023 | Mar 31, 2023 | $789.64K | +30.9% |
| Q4 FY2022 | Dec 31, 2022 | $1.43M | -12.3% |
| Q3 FY2022 | Sep 30, 2022 | $279.35K | -76.7% |
| Q2 FY2022 | Jun 30, 2022 | $207.47K | -53.3% |
| Q1 FY2022 | Mar 31, 2022 | $603.10K | +140.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.64M | +292.6% |
| Q3 FY2021 | Sep 30, 2021 | $1.20M | +45.1% |
| Q2 FY2021 | Jun 30, 2021 | $444.52K | -75.6% |
| Q1 FY2021 | Mar 31, 2021 | $250.58K | – |
| Q4 FY2020 | Dec 31, 2020 | $416.49K | – |
| Q3 FY2020 | Sep 30, 2020 | $827.64K | – |
| Q2 FY2020 | Jun 30, 2020 | $1.82M | – |
See a number that looks wrong?